Principles of Allergen Immunotherapy and Its Clinical Application in China: Contrasts and Comparisons with the USA

Kai Guan, Bin Liu, Meng Wang, Zhi Li, Christopher Chang, Le Cui, Rui Qi Wang, Li Ping Wen, Patrick S Leung, Ji Fu Wei, Jin Lyu Sun

Research output: Contribution to journalReview article

Abstract

Allergen immunotherapy (AIT) for allergic rhinitis (AR), asthma, and other allergic diseases has developed quickly. House dust mite (HDM), Artemisia (wormwood), Humulus japonicus (Japanese hop), Alternaria alternata, and Cladosporium herbarum are the five most common inhalant allergens in China. AIT has been performed in China for over 60 years. With the support of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA), the Chinese College of Allergy and Asthma (CCAA) was established in 2016 as a specialized branch of CDMA and is the main certification authority for AIT. Chinese allergists and scientists have made tremendous progress in the development of AIT. There have been many publications by Chinese allergists and scientists worldwide encompassing original research studies, systematic reviews, case studies, and clinical trials. Currently, conventional subcutaneous immunotherapy (SCIT) is the preferred AIT in China, but sublingual immunotherapy (SLIT) is beginning to gain recognition. An increasing number of clinical trials have been conducted to investigate the clinical efficacy and side effects of SLIT and SCIT. In China, HDM is the only commercial standardized allergen extracts in clinical use, whereas the others are crude allergen extracts. Besides standardized allergen extracts, other forms of hypoallergenic extracts are still being investigated and developed in China. Immunotherapy in China is similar to that in the USA in which allergen extracts can be mixed for SCIT. However, allergen extracts cannot be mixed for SCIT in Europe.

Original languageEnglish (US)
Pages (from-to)128-143
Number of pages16
JournalClinical Reviews in Allergy and Immunology
Volume57
Issue number1
DOIs
StatePublished - Aug 15 2019

Fingerprint

Immunologic Desensitization
Allergens
China
Immunotherapy
Sublingual Immunotherapy
Artemisia
Humulus
Pyroglyphidae
Asthma
Clinical Trials
Cladosporium
Alternaria
Certification
Complex Mixtures
Publications
Hypersensitivity
Research

Keywords

  • Allergen-specific immunotherapy
  • Allergic rhinitis
  • Subcutaneous immunotherapy
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Principles of Allergen Immunotherapy and Its Clinical Application in China : Contrasts and Comparisons with the USA. / Guan, Kai; Liu, Bin; Wang, Meng; Li, Zhi; Chang, Christopher; Cui, Le; Wang, Rui Qi; Wen, Li Ping; Leung, Patrick S; Wei, Ji Fu; Sun, Jin Lyu.

In: Clinical Reviews in Allergy and Immunology, Vol. 57, No. 1, 15.08.2019, p. 128-143.

Research output: Contribution to journalReview article

Guan, Kai ; Liu, Bin ; Wang, Meng ; Li, Zhi ; Chang, Christopher ; Cui, Le ; Wang, Rui Qi ; Wen, Li Ping ; Leung, Patrick S ; Wei, Ji Fu ; Sun, Jin Lyu. / Principles of Allergen Immunotherapy and Its Clinical Application in China : Contrasts and Comparisons with the USA. In: Clinical Reviews in Allergy and Immunology. 2019 ; Vol. 57, No. 1. pp. 128-143.
@article{737e6c094f3c4e2992522fd9b8a5478c,
title = "Principles of Allergen Immunotherapy and Its Clinical Application in China: Contrasts and Comparisons with the USA",
abstract = "Allergen immunotherapy (AIT) for allergic rhinitis (AR), asthma, and other allergic diseases has developed quickly. House dust mite (HDM), Artemisia (wormwood), Humulus japonicus (Japanese hop), Alternaria alternata, and Cladosporium herbarum are the five most common inhalant allergens in China. AIT has been performed in China for over 60 years. With the support of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA), the Chinese College of Allergy and Asthma (CCAA) was established in 2016 as a specialized branch of CDMA and is the main certification authority for AIT. Chinese allergists and scientists have made tremendous progress in the development of AIT. There have been many publications by Chinese allergists and scientists worldwide encompassing original research studies, systematic reviews, case studies, and clinical trials. Currently, conventional subcutaneous immunotherapy (SCIT) is the preferred AIT in China, but sublingual immunotherapy (SLIT) is beginning to gain recognition. An increasing number of clinical trials have been conducted to investigate the clinical efficacy and side effects of SLIT and SCIT. In China, HDM is the only commercial standardized allergen extracts in clinical use, whereas the others are crude allergen extracts. Besides standardized allergen extracts, other forms of hypoallergenic extracts are still being investigated and developed in China. Immunotherapy in China is similar to that in the USA in which allergen extracts can be mixed for SCIT. However, allergen extracts cannot be mixed for SCIT in Europe.",
keywords = "Allergen-specific immunotherapy, Allergic rhinitis, Subcutaneous immunotherapy, Sublingual immunotherapy",
author = "Kai Guan and Bin Liu and Meng Wang and Zhi Li and Christopher Chang and Le Cui and Wang, {Rui Qi} and Wen, {Li Ping} and Leung, {Patrick S} and Wei, {Ji Fu} and Sun, {Jin Lyu}",
year = "2019",
month = "8",
day = "15",
doi = "10.1007/s12016-019-08751-y",
language = "English (US)",
volume = "57",
pages = "128--143",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Principles of Allergen Immunotherapy and Its Clinical Application in China

T2 - Contrasts and Comparisons with the USA

AU - Guan, Kai

AU - Liu, Bin

AU - Wang, Meng

AU - Li, Zhi

AU - Chang, Christopher

AU - Cui, Le

AU - Wang, Rui Qi

AU - Wen, Li Ping

AU - Leung, Patrick S

AU - Wei, Ji Fu

AU - Sun, Jin Lyu

PY - 2019/8/15

Y1 - 2019/8/15

N2 - Allergen immunotherapy (AIT) for allergic rhinitis (AR), asthma, and other allergic diseases has developed quickly. House dust mite (HDM), Artemisia (wormwood), Humulus japonicus (Japanese hop), Alternaria alternata, and Cladosporium herbarum are the five most common inhalant allergens in China. AIT has been performed in China for over 60 years. With the support of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA), the Chinese College of Allergy and Asthma (CCAA) was established in 2016 as a specialized branch of CDMA and is the main certification authority for AIT. Chinese allergists and scientists have made tremendous progress in the development of AIT. There have been many publications by Chinese allergists and scientists worldwide encompassing original research studies, systematic reviews, case studies, and clinical trials. Currently, conventional subcutaneous immunotherapy (SCIT) is the preferred AIT in China, but sublingual immunotherapy (SLIT) is beginning to gain recognition. An increasing number of clinical trials have been conducted to investigate the clinical efficacy and side effects of SLIT and SCIT. In China, HDM is the only commercial standardized allergen extracts in clinical use, whereas the others are crude allergen extracts. Besides standardized allergen extracts, other forms of hypoallergenic extracts are still being investigated and developed in China. Immunotherapy in China is similar to that in the USA in which allergen extracts can be mixed for SCIT. However, allergen extracts cannot be mixed for SCIT in Europe.

AB - Allergen immunotherapy (AIT) for allergic rhinitis (AR), asthma, and other allergic diseases has developed quickly. House dust mite (HDM), Artemisia (wormwood), Humulus japonicus (Japanese hop), Alternaria alternata, and Cladosporium herbarum are the five most common inhalant allergens in China. AIT has been performed in China for over 60 years. With the support of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA), the Chinese College of Allergy and Asthma (CCAA) was established in 2016 as a specialized branch of CDMA and is the main certification authority for AIT. Chinese allergists and scientists have made tremendous progress in the development of AIT. There have been many publications by Chinese allergists and scientists worldwide encompassing original research studies, systematic reviews, case studies, and clinical trials. Currently, conventional subcutaneous immunotherapy (SCIT) is the preferred AIT in China, but sublingual immunotherapy (SLIT) is beginning to gain recognition. An increasing number of clinical trials have been conducted to investigate the clinical efficacy and side effects of SLIT and SCIT. In China, HDM is the only commercial standardized allergen extracts in clinical use, whereas the others are crude allergen extracts. Besides standardized allergen extracts, other forms of hypoallergenic extracts are still being investigated and developed in China. Immunotherapy in China is similar to that in the USA in which allergen extracts can be mixed for SCIT. However, allergen extracts cannot be mixed for SCIT in Europe.

KW - Allergen-specific immunotherapy

KW - Allergic rhinitis

KW - Subcutaneous immunotherapy

KW - Sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85068211849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068211849&partnerID=8YFLogxK

U2 - 10.1007/s12016-019-08751-y

DO - 10.1007/s12016-019-08751-y

M3 - Review article

C2 - 31243705

AN - SCOPUS:85068211849

VL - 57

SP - 128

EP - 143

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 1

ER -